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Abstract 
Background and objective: Live vaccines may have beneficial non-specific effects. We tested 
whether the live measles, mumps and rubella (MMR) vaccine compared with the non-live 
diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus-influenzae-type-b (DTaP-
IPV-Hib) vaccine as the most recent vaccine was associated with less childhood asthma and 
fewer acute hospital contacts for childhood asthma among boys and girls.  
Methods: This study is a nationwide register-based cohort study of 338 761 Danish children 
born 1999-2006. We compared 1) the incidence of first-registered childhood asthma based on 
hospital contacts and drug prescriptions and 2) the incidence of severe asthma defined as acute 
hospital contacts for childhood asthma between 15 and 48 month among children who latest 
had received 3 doses of DTaP-IPV-Hib and then MMR with children who latest had received 3 
doses of DTaP-IPV-Hib.  
Results: For boys, following the recommended vaccine schedule of MMR after DTaP-IPV-Hib3 
compared with DTaP-IPV-Hib3 as the latest vaccine, MMR was associated with 8.0 (95% 
confidence interval 3.9-12.2) fewer childhood asthma cases per 1,000 boys, corresponding to 
10% (5-15%) reduction in the cumulative incidence of childhood asthma. MMR, when given last, 
was also associated with 16.3 (12.7-19.9) fewer acute hospital admissions for childhood asthma 
per 1,000 boys, corresponding to a 27% (22-31%) reduction in the cumulative incidence. No 
associations were seen for girls.  
Conclusion: MMR may have a protective effect against childhood asthma for boys. This calls for 
an understand of whether non-specific effects of vaccines can be used to optimise our vaccine 
programmes. 
Key Messages 
• The live measles, mumps and rubella (MMR) vaccine as the most recently received 
vaccine may reduce childhood asthma. 
• In a Danish population of children aged 15-48 months, the measles, mumps and rubella 
vaccine compared with the non-live diphtheria-tetanus-acellular-pertussis-inactivated-
polio-haemophilus-influenzae-type-b vaccine (DTaP-IPV-Hib) as the most recent 
vaccine was associated with less childhood asthma and less severe asthma for boys. 
• Timely MMR after DTaP-IPV-Hib may protect one in 124 (95% CI 82 to 260) boys in the 
age between 15-48 months from childhood asthma. 
• This potential calls for a better understanding of non-specific effects of vaccines. 
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Introduction 1 
Vaccines may have beneficial non-specific effects (NSEs).(1-4) Live vaccines affect the innate 2 
immune system beneficially leading to increased response to unrelated pathogens(2) and are 3 
associated with lower morbidity and mortality from non-targeted diseases. (1,3-7) Studies 4 
suggest that live vaccines induce a T-helper 1 cell dominant shift reducing atopic 5 
diseases.(4,8,9) In contrast, non-live vaccines can induce tolerance of the innate immune system 6 
leading to decreased responses to unrelated pathogens(2) and have been associated with 7 
higher morbidity and mortality from non-targeted diseases.(1,3-7) The non-specific effects of 8 
live vaccines are most pronounced as long as a given vaccine is the most recent vaccine and 9 
may vary by sex.(4,8,9) 10 
Studies of the live measles, mumps, and rubella (MMR) vaccine and childhood asthma have 11 
reported preventive effects(10-13), detrimental effects(14) or no effect(15-19). However, 12 
vaccination sequence was not assessed in any of the studies (10-19) and sex-differential effects 13 
was only assessed in one study(11). 14 
The main objective of this study was to test the hypothesis that the live MMR vaccine as the 15 
most recent vaccine compared with the non-live diphtheria-tetanus-acellular pertussis-polio-16 
Haemophilus Influenzae type b (DTaP-IPV-Hib) vaccine is associated with a lower incidence of 17 
childhood asthma defined by hospital contacts and drug prescriptions in Danish children aged 18 
15 to 48 months (hypothesis 1). Our secondary objective was to test whether MMR was 19 
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associated with a lower incidence of severe childhood asthma defined by acute hospital 20 
contacts (hypothesis 2). We examined whether associations differed by sex. 21 
Method 22 
This study is a register-based cohort study of Danish children followed from the age of 15 23 
months until the age of 48 months for the risk of childhood asthma according to whether their 24 
last vaccine received was DTaP-IPV-Hib. Linkage across Danish nation-wide registers is possible 25 
using Danish personal identification numbers assigned to all new-borns. We used information 26 
from The Danish Civil Registration System, the Danish National Health Service Register, the 27 
Danish National Patient Register, the Danish National Prescription Register, the Danish Medical 28 
Birth Register, and information from Statistics Denmark (Supplementary information 1). 29 
Study base and vaccinations 30 
To reduce interference from other vaccines than MMR and DTaP-IPV-Hib, the study base was 31 
children born in Denmark from 1 July 1999 until and including 30 September 2006 and 32 
followed from 15 months of age until 48 months of age (Supplementary figure 1). For this study 33 
base, the Danish childhood vaccination programme until 48 months of age was three doses of 34 
the non-live DTaP-IPV-Hib at 3, 5, and 12 months of age and the first dose of the live MMR at 35 
15 months of age.  36 
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In Denmark, vaccines are administered free-of-charge by the general practitioners. For the 37 
purpose of reimbursement, information about vaccine type, dose, and week of vaccination is 38 
collected in the Danish National Health Service Register.(20)  39 
Childhood asthma 40 
Asthma in young children may be differentiated by multiple phenotypes(21) and multiple ways 41 
of phenotyping.(22) Asthma, asthmatic bronchitis and infection induced wheezing in young 42 
children are difficult to separate using register data, hence we used the term “childhood 43 
asthma” to cover the aforementioned diseases. 44 
Childhood asthma was defined by information from two sources: 1) the Danish National Patient 45 
Register(23) holds information on hospital contacts coded with the 10th version of the 46 
international classification of diseases (ICD-10); 2) The Danish National Prescription Register(24) 47 
holds information about all redeemed prescriptions in Danish pharmacies. 48 
The main outcome (hypothesis 1) was the incidence of first-registered childhood asthma 49 
between 15 to 48 months of age defined as the first registration of a hospital contacts 50 
(outpatients, inpatients, and emergency room) according to ICD-10 codes J45 (Asthma) and J46 51 
(Status asthmaticus) or the first prescription of inhaled glucocorticoids (R03BA) or montelukast 52 
(R03DC03) (at least 2 prescriptions of either glucocorticoids or montelukast within 12 months). 53 
Our second outcome (hypothesis 2) was severe childhood asthma between 15 to 48 months of 54 
age defined as the incidence of all acute hospital contacts (inpatients and emergency room 55 
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visits) with ICD-10 codes J45 or J46. Allowing for recurrent events, adjacent acute hospital 56 
contact periods within 5 days of last hospital discharge counted as one acute hospital contact. 57 
Inclusion and exclusion criteria 58 
To ensure that the study population consisted of children, who followed the vaccination 59 
schedule before the baseline of our study, only children who had received the first two doses of 60 
DTaP-IPV-Hib before the age of 11 months were included. For hypothesis 1, we excluded 61 
children who had been registered with childhood asthma before 15 months of age, while this 62 
restriction did not apply for hypothesis 2, since it focused on repeated events (Figure 1 and 63 
Supplementary figure 2). 64 
Sequence cohorts 65 
A proportion of Danish children deviate from the recommended schedule of the childhood 66 
vaccination programme. This variation allows us to investigate the robustness of the analyses in 67 
three partly overlapping vaccine sequence cohorts (Figure 1); recommended sequence (DTaP-68 
IPV-Hib1-3-then-MMR vs DTaP-IPV-Hib1-3 only), early MMR sequence (DTaP-IPV-Hib1-2-then-69 
MMR vs DTaP-IPV-Hib1-2 only) and interrupted sequence (DTaP-IPV-Hib1-2-then-MMR vs 70 
DTaP-IPV-Hib1-2-then-MMR-then-DTaP-IPV-Hib3). 71 
Follow-up 72 
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For hypothesis 1, all children entered the study at the first Sunday after they turned 15 months 73 
of age or when their vaccination sequence qualified them for one of the sequence cohorts 74 
described above, whichever occurred last. All children left the study: a) at the date of a 75 
registered childhood asthma event, b) at 48 months of age, c) when receiving more than one 76 
vaccine in one day or receiving unrelated vaccines, or d) 12 months before emigrating or dying, 77 
to allow two prescriptions to be registered within a year, whichever occurred first. For 78 
hypothesis 2, the same entry and exit criteria applied, except that children registered with an 79 
acute hospital contact for childhood asthma left the study for 5 days and re-entered the study 80 
to make sure that we did not count one episode several times. 81 
Statistical methods 82 
We suspected that hospital admissions due to infectious diseases could both affect vaccination 83 
status(25,26) and later childhood asthma(27,28); furthermore hospital admissions due to 84 
infectious diseases have been shown to be reduced by prior MMR vaccination(4,29) (illustrated 85 
in Supplementary figure 3). This is known as time-varying confounding. We attempted to 86 
control for this potential issue using weights, which we updated each week based on 22 87 
covariates (Supplementary information 1 and 2). Such an approach is well-established and aims 88 
at creating comparable comparison groups at any given time during follow up.(30,31) We have 89 
added a technical description in Supplementary information 2. 90 
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We calculated the crude and weighted cumulative incidence rates and reported the cumulative 91 
incidence rate reduction per 1,000 children for each group at 48 months of age (wIRreduction48) 92 
and cumulative incidence rate ratios at 48 months of age. Standard errors were calculated using 93 
robust estimators and confidence intervals were estimated with 2.5% and 97.5% quantiles using 94 
100,000 simulations. The analyses assumed independent observations. A spline function of the 95 
crude and weighted cumulative incidence rates were plotted for each analysis. We investigated 96 
whether the wIRreduction48 were different for girls and boys. Additionally, to compare with 97 
hazards ratios often reported in the medical literature, we used a weighted Cox proportional 98 
hazards model to estimate hazard ratios. The weighted Cox proportional hazards model had 99 
age as the underlying time scale and was stratified by week (Sunday to Saturday) of birth 100 
thereby adjusting for the effect of age and calendar time. We tested the assumption of 101 
proportional hazards using Schoenfeld residuals.  102 
Sensitivity analysis 103 
Since infections may affect childhood asthma(27,28) and MMR has been associated with fewer 104 
infections in the same cohort(4), we conducted a sensitivity analysis excluding hospital 105 
admissions with childhood asthma co-occurring with hospital admissions for an infectious 106 
disease, to ensure we did not partly reproduce earlier results. 107 
If childhood asthma was registered using two prescriptions within one year, we used the first 108 
date of two prescriptions. Thus, the registered childhood asthma date was conditioned on a 109 
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future prescription, which could cause a collider bias introducing a non-causal association 110 
between MMR vaccination and the first prescription for childhood asthma. We conducted a 111 
sensitivity analysis using the second date of prescriptions. 112 
Furthermore, we conducted a sensitivity analysis of the effect of DTaP-IPV-Hib 3 vs DTaP-IPV-113 
Hib 2 from 12 to 15 months of age under the hypothesis that the incidence of new-onset 114 
childhood asthma and severe asthma would not differ. If DTaP-IPV-Hib 3 is associated with a 115 
reduced incidence of asthma compared with DTaP-IPV-Hib 2 in spite of adjustment for 116 
potential confounding, this would suggest that we have been unable to fully control for 117 
confounding i.e. that the most healthy children receive the next vaccine (residual confounding 118 
of a“healthy vaccinee effect”-bias)Data was analysed using Stata 14.0 and R 3.3.1 with version 119 
1.0-11 for the ipw package. Register based studies do require ethical approval by the Danish 120 
Central Scientific Ethics Committee. 121 
Results 122 
From the study base of 467,919 children, 338,761 children were eligible for studying hypothesis 123 
1 (Figure 1) and 364,270 children were eligible for hypothesis 2 (Supplementary figure 2). The 124 
recommended sequence included the majority of risk time with 773,054 person years of follow 125 
up (pyrs), the early MMR sequence had 50,918 pyrs, and the interrupted sequence had 36,788 126 
pyrs. 127 
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Most shifts in vaccination sequence cohorts happened between 15-20 months of age 128 
(Supplementary figure 4 and 5). Childhood asthma peaked at 8 months of age, and boys have a 129 
higher incidence than girls (Supplementary figure 6). Among the recommended sequence for 130 
hypothesis 1, 18 776 children were registered with childhood asthma during follow-up (of 131 
which; 25% based on hospital contacts, 74% based on glucocorticoids, and 1% based on 132 
montelukast). 133 
Covariates were approximately similarly distributed between vaccination sequence groups at 16 134 
months of age (Supplementary table 1). However, children who had received only DTaP-IPV-135 
Hib 1 + 2 at 16 months of age tended to have a skewed distribution compared with the 136 
remaining vaccination sequence groups especially regarding single parenthood, family income, 137 
maternal education, other children in the household, mother smoking during pregnancy, and 138 
previous infectious diseases and prescribed antibiotics. 139 
For hypothesis 1, MMR compared with DTaP-IPV-Hib as most recent vaccine was associated 140 
with a weighted cumulative incidence reduction of childhood asthma per 1,000 children at 48 141 
months of age (wIRreduction48) of 4.5 (95% confidence interval (CI) 1.7 to 7.2), 3.8 (95% CI -3.3 142 
to 10.8), and 22.9 (95% CI 3.1 to 42.7) for the recommended, early, and interrupted sequence 143 
respectively (Table 1). The incidence diverged mostly in the first part of follow-up (Figure 2). 144 
The incidence difference tended to be larger among boys than girls (Table 2). 145 
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For hypothesis 2, MMR compared with DTaP-IPV-Hib as the last received vaccine was 146 
associated with a wIRreduction48 of 8.2 (95% CI 6.0 to 10.5), 13.4 (95% CI 7.3 to 19.4), and 1.7 147 
(95% CI -11.8 to 15.2)  for the rate of acute hospital contacts for childhood asthma in the 148 
recommended, early and interrupted sequence (Table 3 and figure 3). Again, the association 149 
was strongest among boys compared with girls in the recommended sequence (Table 4). 150 
When analysing the hypotheses using hazard ratios, the assumption of proportional hazards 151 
was not met for hypothesis 1 (Supplementary table 2) but was more stable for hypothesis 2 152 
(Supplementary table 3).  153 
Excluding concurrent hospital contacts for infectious diseases and using the date of the second 154 
prescription provided similar estimates (Supplementary tables 4, 5 and 6). 155 
The weighted cumulative incidence difference from 12 to 15 months of age per 1,000 children 156 
for DTaP-IPV-Hib 3 compared with DTaP-IPV-Hib 2 for the hypothesis 1 and 2 outcomes were 157 
respectively 2.7 (95% CI 1.6 to 3.8) and 0.6 (95% CI -0.1 to 1.3). The association tended to be 158 
stronger among boys than girls (Supplementary tables 7 and 8). 159 
Discussion 160 
Among boys but not girls, MMR vaccination compared with DTaP-IPV-Hib as the last received 161 
vaccine across cohorts was associated with a lower incidence of childhood asthma and fewer 162 
acute hospital contacts for childhood asthma.  163 
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Strengths and weaknesses 164 
This was a large nationwide study and we applied state of the art statistical methods, the 165 
weighted approach, to handle potential time-varying confounding.(32) The weights were not 166 
extreme so no single individual affected the results disproportionally (Supplementary figure 7). 167 
The 95% confidence interval for the incidence rate difference was calculated assuming 168 
independent observations, which is a limitation as children have contributed risk time to both 169 
vaccination groups.  170 
By ensuring that children had followed the vaccination programme (received DTaP-IPV-Hib 1 171 
and 2 before 11 months of age) we increased homogeneity of the study population(33) and by 172 
including many potential confounders, we may to some extent have controlled for unmeasured 173 
confounding though it cannot be ruled out. Potential time-varying confounding due to 174 
children’s health status was modelled by previous chronic diseases as well as hospital 175 
admissions and antibiotic use for infectious diseases. The comparison between DTaP-IPV-Hib 3 176 
and DTaP-IPV-Hib 2 for the hypothesis 1 and to some degree hypotheses 2 suggests that there 177 
may be confounding not fully adjusted for (residual confounding of a “healthy vaccinee 178 
effect”-bias). However, in the interrupted sequence cohort, children who received the next 179 
vaccine (DTaP-IPV-Hib 3 after MMR) had a higher risk for childhood asthma compared with 180 
those who had only received MMR, which indicates that a “healthy vaccinee effect”-bias does 181 
not fully explain our results Receiving the MMR vaccine as the last vaccine was associated with 182 
approximately similar cumulative incidence rates across sequences, while DTaP-IPV-Hib in 183 
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contrast was associated with greater cumulative incidence rates. As this pattern was 184 
independent of which sequence children followed, it suggests that both vaccines affect the risk 185 
of childhood asthma respectively beneficially and detrimentally. 186 
MMR vaccination coverage in Denmark may be underreported,(34) which would increase 187 
proportionally with time if MMR vaccinated children stay categorised as DTaP-IPV-Hib 3 188 
vaccinated thus biasing the estimate towards null over time – a pattern we also observed. The 189 
inclusion criteria DTaP-IPV-Hib 1 and 2 before 11 months of age decreased the misclassification 190 
of the reference groups in the recommended sequence and early MMR sequence.  191 
Unsystematic underreporting would also cause conservative estimates. Simultaneous 192 
administration of vaccines was outside the scope of our analysis.  193 
Neither of our sensitivity analyses indicated that we should have reached other conclusions. 194 
Further analyses indicated that it was the first prescription of childhood asthma prescription 195 
rather than the criteria of two prescriptions within one year that captured the effect of MMR on 196 
childhood asthma (analysis not shown). 197 
Studies on MMR and childhood asthma 198 
No randomised trial has studied the effect of MMR on the risk of childhood asthma; nine 199 
diverse observational studies on the effect of MMR or measles vaccines on childhood asthma 200 
show conflicting results (Supplementary table 9). (10-19) The nine studies vary from large 201 
prospective cohort studies to small cross-sectional studies and represent children from 11 202 
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countries (two sets of studies partly overlap in study populations[(16,17) and (18,19)] and one 203 
study partly overlap with the study population of our study(11)). The studies were further 204 
heterogenic with regards to outcome definition, age group and sequence of vaccines. 205 
Specifically, our study indicated that the effect of vaccine status on the incidence of childhood 206 
asthma decreased with age, making comparisons for unlike age groups problematic. Our study 207 
is the first study to strictly investigate the effect of having MMR as the most recent vaccine on 208 
the risk of childhood asthma. Not differentiating the vaccine sequence mixes effects of multiple 209 
vaccine combinations,(35) a problem, which was highlighted in a recent WHO review of non-210 
specific effects of vaccines(3) and also supported by this study. Furthermore, applying the 211 
inclusion criteria where all children had received the first two doses of DTaP-IPV-Hib before 11 212 
months of age increased the exchangeability of the comparison groups in our study compared 213 
with the previous studies. Despite differences in design, the study overlapping with the study 214 
population of our study found similar effects of MMR on the use of glucocorticoids and for 215 
hospital admissions due to asthma.(11) However, they did not find similar sex differential 216 
effects for hospital admissions due to asthma, which may have been masked by the effects of 217 
other vaccines. 218 
Biological mechanisms 219 
Successful immunisation by live vaccines, like natural infections, has been shown to shift from a 220 
predominant and often hyper reactive T-helper 2 cell to being T-helper 1 cell predominant that 221 
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allows an accelerated clearance of infections,(1) and thus a potentially reduced risk of 222 
childhood asthma. 223 
MMR compared with DTaP-IPV-Hib as the most recent vaccine has been associated with fewer 224 
admissions for infectious diseases.(4) Since persistent respiratory infections may destroy 225 
epithelial cells of the respiratory tract making children with childhood asthma more prone to 226 
severe episodes(36) and as respiratory infections can function as irritants exaggerating wheeze 227 
attacks(9), then a reduction in infectious diseases could lead to a lower risk of childhood 228 
asthma. 229 
Recent cutting edge immunological research show that live vaccines can train the innate 230 
immune system for swifter clearance of non-related pathogens possible through epigenetic 231 
reprogramming.(2) In accordance with our results indicating that males benefited more from 232 
the MMR vaccine, a new immunological study of Gambian children showed that measles 233 
vaccine was associated with enhanced proinflammatory innate responses for males but not for 234 
females possibly by modifying signaling via Toll-like receptor 4 (TLR4).(37) The duration of 235 
trained immunity is yet unknown, but according to our data the absolute risk difference was 236 
proportionally largest the first 10-15 months after vaccination and waned off (Figures 2 and 3).  237 
Conclusion 238 
Our study indicated that boys experience less childhood asthma and fewer acute hospital 239 
contacts for childhood asthma when the live MMR vaccine compared with the non-live DTaP-240 
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IPV-Hib vaccine was the most recent vaccine. Data did not convincingly suggest an effect for 241 
girls. For now, these results are only indications, thus we hope other research groups will test 242 
our findings that MMR compared with DTaP-IPV-Hib as most recent vaccine reduces the risk of 243 
childhood asthma among boys and investigate why girls may not experience the same benefit. 244 
If supported, the question of whether a beneficial effect of MMR would persist or be countered 245 
by a subsequent non-live vaccine should be addressed. 246 
If our estimates are correct then for 1,000 boys following the recommended vaccine schedule 247 
and receiving MMR timely after DTaP-IPV-Hib, MMR prevents 8.0 (95% CI 3.9 to 12.2) 248 
childhood asthma cases between 15 months and 48 months. Thus, one childhood asthma case 249 
is prevented for each 124 (95% CI 82 to 260) MMR vaccinations administrated. Though most 250 
childhood asthma cases occurred before 15 months of age in this study, potential immune 251 
modulation via MMR or other approaches for preventing childhood asthma calls for a better 252 
understanding of non-specific effects of vaccines.(38) 253 
Supplementary material 
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